Clinical Trial Update: Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating irinotecan liposome in combination with S-1 for PD-1/PD-L1 inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma; curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Onivyde (irinotecan hydrochloride liposome injection)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Status: RECRUITING